Janssen is the last of the vaccines applied in Brazil to receive definitive registration. Pfizer/BioNTech, AstraZeneca/Oxford, and Coronavac already have their definitive registrations granted by Anvisa.
According to the European Medicines Agency, the recommendation is based on data showing increased antibodies" against the covid-19 virus.
The information is contained in the first edition of the bulletin on the effectiveness of vaccines against covid-19 in the Brazilian population, from the Vigivac project by Fiocruz, published on the 9th.
Data from the Ministry of Health indicate a drop in the rate of hospitalizations and deaths for covid-19 amid the increase in vaccination in the country.
Anvisa wants data from developers on authorized vaccines and evaluation of the impact of variants on their effectiveness. For the population, it is a moment of caution, says the agency.
Português 
Español 
